



Standing Way Eaglestone Milton Keynes MK6 5LD 01908 660033 www.mkuh.nhs.uk

12 February 2025

## Request under Freedom of Information Act 2000

Thank you for your request for information which we received on Thursday 6 January 2025. I am pleased to confirm the following.

A. Please provide the number of migraine patients treated in the last 4 months with:

• /	Atogepant (Aquipta)	3 patients
-----	---------------------	------------

- Erenumab (Aimovig)
- Eptinezumab (Vyepti)
- Fremanezumab (Ajovy)
- Galcanezumab (Emgality)
- Rimegepant (Vydura)
- Botulinum Toxin (i.e., Botox, Dysport, Xeomin) Botulinum can be used for many indications and we do not hold information specifically for treating migraines.

58 patients

0 patients

7 patients

0 patients

1 patient

B. How many patients have you treated in the last 4 months for chronic migraine (15+ headache days per month) and episodic migraine (4-15 headache days per month) with the following drugs:

Drugs	Chronic Migraine (15+ headache days per month)	Episodic Migraine (4-15 headache days per month)
Atogepant	3	0
Erenumab (3 UNKNOWN)	36	19
Eptinezumab	0	0
Fremanezumab	7	0
Galcanezumab	0	0
Rimegepant	0	1
Botulinum Toxin	N/A	N/A

## C. How many patients have you treated in the last 4 months for acute migraine with:

• Rimegepant (Vydura) 0 patients





## D. Does the trust actively initiate a treatment pause (usually at 12 months) of anti-CGRP (calcitonin gene-related peptide inhibitors) migraine treatment with the aim to re-start treatment if the patient continues to fit the criteria (Yes/No)?

As per agreed BLMK guidelines, patients take a break after 15 months (3-month trial period and then after a further 12 months). Treatment restarts if migraines return.

Please be advised that this information is provided in accordance with the Freedom of Information Act 2000 and is for your personal use. Any re-use of this information will be subject to copyright and the Re-Use of Public Sector Information Regulations (1st July 05) and authorisation from Milton Keynes Hospital NHS Foundation Trust will be required. In the event of any re-use, the information must be reproduced accurately and not used in a misleading manner.

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely

Information Governance Administrator For and on behalf of Milton Keynes Hospital NHS Foundation Trust

Any re-use of this information will be subject to the 'Re-use of Public Sector Information Regulations' and best practice.